MedTrace Logo

NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients

NCT01771705 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-05-21

No results posted yet for this study

Summary

The purpose of this study is to compare two different ways of monitoring the immune system to determine how to manage the doses of anti-rejection medications.

Conditions

  • Kidney Transplantation

Interventions

OTHER

Dose adjust group (NFAT)

If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is \> 60% the CNI daily dose will be increased by 15%.

Sponsors & Collaborators

Principal Investigators

  • Flavio Vincenti, M.D. · University of California, San Francisco

  • Allison Webber, M.D. · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-02
Primary Completion
2016-08-13
Completion
2017-04-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01771705 on ClinicalTrials.gov